Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma.

Cancers·2026
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.

Journal of neuro-oncology·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Current and emerging therapies in IDH-mutant glioma.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.

Neuro-oncology advances·2026

Related Experiment Video

Updated: Dec 20, 2025

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.7K

Lower Grade Gliomas.

Gilbert Youssef1, Julie J Miller2

  • 1Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.

Current Neurology and Neuroscience Reports
|May 24, 2020
PubMed
Summary

This review covers recent advances in low-grade gliomas (LGG), focusing on IDH-mutated brain tumors. New insights into molecular features and targeted therapies offer hope for improved patient outcomes beyond current treatments.

Keywords:
1p/19 codelAstrocytomasIDH inhibitorsIDH mutationLow-grade gliomasOligodendrogliomasPARP inhibitors

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

967
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.3K

Related Experiment Videos

Last Updated: Dec 20, 2025

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.7K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

967
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.3K

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Genetics

Background:

  • Low-grade gliomas (LGG) are primary brain tumors affecting young adults.
  • Characterized by isocitrate dehydrogenase (IDH) mutations, they include astrocytomas and oligodendrogliomas.
  • Current treatment involves surgery, radiation, and chemotherapy, with limited curative potential.

Purpose of the Study:

  • To review recent clinical and molecular research on LGG.
  • To explore innovative therapeutic modalities for IDH-mutated gliomas.
  • To highlight the impact of new findings on treatment strategies.

Main Methods:

  • Review of recent scientific literature on LGG.
  • Analysis of clinical and molecular classifications.
  • Examination of IDH mutation-related metabolic effects and targeted therapies.

Main Results:

  • Newly identified features are integrated into LGG classification and treatment planning.
  • Enhanced understanding of IDH mutation-induced metabolic effects.
  • Emerging targeted therapies show potential for improved patient outcomes.

Conclusions:

  • Recent advances may lead to a paradigm shift in LGG treatment.
  • Current therapies are not curative, necessitating novel interventions.
  • Targeted therapies hold promise for more effective management of IDH-mutated gliomas.